Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

🤖 Plain-English Summary

BACKGROUND: Lu)-PSMA-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment. CONCLUSIONS: Lu-PSMA-617 prolonged imaging-based progression-free survival and overall survival when added to standard care in patients with advanced PSMA-positive metastatic castration-resistant prostate cancer.

🔑 Key Findings

• METHODS: Ra), and investigational drugs.
• The alternate primary end points were imaging-based progression-free survival and overall survival, which were powered for hazard ratios of 0.67 and 0.73, respectively.
• Key secondary end points were objective response, disease control, and time to symptomatic skeletal events.

🔗 Related Resources